New Delhi, March 6 -- Danish drugmaker Novo Nordisk is prepared to enter the Indian market and other markets with its blockbuster drug Ozempic, despite losing patent exclusivity early next year.

"Even as we face patent expiration for Semaglutide, we'll probably still launch the product in markets and [drive] volume growth, and to do that we need to have a very large manufacturing footprint," Lars Fruergaard Jørgensen, Novo Nordisk's chief executive officer, said in a press briefing on Thursday.

"We're using the years of successful growth to invest in that capacity," he added.

Also Read | Investors seek answers on Novo Nordisk's next-gen obesity drug CagriSema

Novo Nordisk's GLP-1 drug Semaglutide, sold under brand names Ozempic a...